Production & Sales

Fujifilm to buy Biogen’s Danish biologics manufacturing site for $890m

Fujifilm has agreed to acquire to acquire Biogen (Denmark) Manufacturing ApS, a large-scale biologics manufacturing site located in Hillerød near Copenhagen, Denmark (Biogen Hillerød), for about $890m in cash.

Ligand sells Promacta assets and Royalty for $827m

Ligand Pharmaceuticals and Royalty Pharma announce the sale of Ligand’s Promacta-related intellectual property rights licensed to Novartis, including the royalty stream on worldwide net sales of Promacta to Royalty Pharma for $827m in cash.

Sagent Pharmaceuticals announces acquisition of Raleigh manufacturing site

Nichi-Iko Pharmaceutical and Sagent Pharmaceuticals, a Nichi-Iko Group Company ("Sagent"), a leader of specialty pharmaceutical products with an emphasis on the injectable market, announced that Sagent has acquired an FDA-approved manufacturing site in Raleigh, North Carolina, from Xellia Pharmaceuticals ("Xellia").

Bausch Health to buy certain assets of Synergy Pharmaceuticals

Bausch Health announced that the company was selected as the successful bidder to acquire certain assets of Synergy Pharmaceuticals for a cash purchase price of approximately $195m and the assumption of certain assumed liabilities, pursuant to the terms of the stalking horse asset purchase agreement previously entered into with the company.

Danaher agrees to buy GE’s biopharma business for $21.4bn

Science and technology firm Danaher has agreed to acquire the biopharma business of GE Life Sciences (GE Biopharma) for a cash purchase price of about $21.4bn.

Indivior introduces generic version of Suboxone opioid drug in US

The US affiliate of specialty pharmaceutical company Indivior has introduced an authorized generic version of Suboxone (buprenorphine and naloxone) sublingual film in the US.

Clinigen to acquire US rights to Novartis cancer drug Proleukin

UK-based Clinigen Group has agreed to acquire the US rights to Proleukin (aldesleukin, human recombinant interleukin-2) from Novartis in an all-cash deal worth up to $210m.

World’s largest pharmaceutical firm selects ValGenesis to standardize corporate validation process enterprise-level

ValGenesis has announced that one of the world's largest, top rated life science companies has chosen to implement its 100% paperless Validation Lifecycle Management System (VLMS) across all its global sites to manage the corporate validation lifecycle process.

Mayne Pharma launches Lexette (halobetasol propionate) foam 0.05% in US

Mayne Pharma Group, a specialty pharmaceutical company focused on applying its drug delivery expertise to commercialize branded and generic pharmaceuticals, has launched LEXETTE (halobetasol propionate) Foam 0.05% in the US.